top of page
Home
Technology
Pipeline
Female Stress Urinary Incontinence
About Us
Open Positions
Investors & Media
Contact
More...
Use tab to navigate through the menu items.
ALL POSTS
NEWS
MEDIA
RESOURCES
AWARDS
PUBLICATIONS
Search
MUVON Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell-based Tissue-Engineered Therapy Showing Significant & Clinically Meaningful Benefits in Stress Urinary Incontinence
MUVON Therapeutics Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell-based Tissue-Engineered Therapy Showing Statistically Significant & Clinically Meaningful Benefits in Stress Urinary Incontinence
3 days ago
4 min read
Deana Mohr nominated as finalist for SEF.WomenAward 2026
Deana Mohr, CEO of MUVON, nominated as finalist for SEF.WomenAward 2026
Nov 14
1 min read
Dr. Thomas Meier elected as new Chairman of the Board of Directors at MUVON Therapeutics’ Annual General Meeting 2025
Zurich, Switzerland, July 01, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, appoints Thomas Meier as...
Jul 1
2 min read
INVEST IN OUR
INNOVATION
MORE INFORMATION
Invest in us to be part of a groundbreaking journey toward innovative, life-changing muscle regeneration therapies, addressing a massive global market with scalable solutions.
bottom of page
